Literature DB >> 22249869

A multi-centre study on the long-term benefits of tinnitus management using Neuromonics Tinnitus Treatment.

Dayse Vieira1, Robert Eikelboom, Gemma Ivey, Stuart Miller.   

Abstract

INTRODUCTION: The Neuromonics Tinnitus Treatment is based on individually customized acoustic stimulation and structured counseling.
OBJECTIVES: To assess the long-term clinical outcomes of the Neuromonics Tinnitus Treatment, specifically, to determine whether benefits achieved at the conclusion of the prescribed treatment program were retained over the longer term.
MATERIALS AND METHODS: This study involved 70 subjects who had previously undergone the treatment across six clinics located in Australia and United States. Patients had concluded the treatment at least six, and up to 36 months, before the commencement of this study. The Tinnitus Reaction Questionnaire was used to assess tinnitus distress, and patients were asked to report on percentage of time of awareness of and disturbance by their tinnitus. Long-term data were compared to data reported throughout the course of the treatment. RESULTS AND
CONCLUSIONS: Patients achieved statistically significant improvement of their tinnitus distress. The success rate (at least 40% reduction in TRQ score) for this cohort of patients was 75.7% at the conclusion of the program and the majority of patients sustained the benefits in the long-term. Results revealed that NTT provides a consistent and stable relief of tinnitus distress.

Entities:  

Mesh:

Year:  2011        PMID: 22249869

Source DB:  PubMed          Journal:  Int Tinnitus J        ISSN: 0946-5448


  2 in total

Review 1.  The state of the art of sound therapy for subjective tinnitus in adults.

Authors:  Haiyan Wang; Dongmei Tang; Yongzhen Wu; Li Zhou; Shan Sun
Journal:  Ther Adv Chronic Dis       Date:  2020-09-14       Impact factor: 5.091

Review 2.  A State-of-Art Review of Digital Technologies for the Next Generation of Tinnitus Therapeutics.

Authors:  Grant D Searchfield; Philip J Sanders; Zohreh Doborjeh; Maryam Doborjeh; Roger Boldu; Kevin Sun; Amit Barde
Journal:  Front Digit Health       Date:  2021-08-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.